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Background:  Value  chain  analyses  are  commonly  used  to understand  socioeconomic  and  power  relation-
ships  in  the  production  chain  from  the  initial  starting  material  to a ﬁnal  (generally  high  value)  product.
These  analyses  help  in  terms  of  understanding  economic  processes  but  also  have  been used in the  context
of socioeconomic  and  socioecological  research.
Aims of  the  study:  However,  there  is  a gap  in  the  ethnopharmacological  literature  in  terms  of understanding
what  relevance  a  critical  analysis  of  value  chains  of  herbal  medicines  could  have.  Here  we  provide  a
research  framework  for  achieving  such  an analysis.
Methods: An  extensive  review  of  the  literature  available  on value  chains  and  their  analysis  was  conducted,
based  both  on a  systematic  online  search  of  the  relevant  literature  and a  hand  search  of bibliographies
and  discussions  with  experts  in  value  chain  analysis
Results:  While  the  concept  of  value  chains  is  commonly  used  in  the  relevant  industries,  very  few  studies
investigate  the  value  chains  of  herbal  medicines  and  products  derived  from  them.  The  studies  identiﬁed
mostly  look  at  socio-ecological  aspects,  especially  in  the  context  of sustainable  resource  use.  We  suggest
an analytical  framework  which  can help  in  understanding  value  chains  in the  context  of  ethnopharma-
cology  and  can  serve  as a basis  for addressing  questions  related  to value  chains  and  their  relevance  in
ethnopharmacology.
Conclusions:  We  identiﬁed  a  crucial  gap  in  current  ethnopharmacological  and  medicinal  plant  research
which  impacts  on  a wide-range  of  factors  relevant  for a sustainable,  socio-culturally  equitable  and  safe
es.supply of herbal  medicin
. The concept of value chains
In this commentary we discuss the concept of value chains
peciﬁcally as it relates to their role in the creation of
roducts and value from local ethnopharmacological resources
nd its relevance for research on medicinal and health food
lants.
In a broad sense a value chain describes the sequence of activities
equired to make a ﬁnished product from its initial starting material
e.g. from ﬁeld crop or gathered wild material) (Chopra and Meindl,
004). Value chain research focuses on the nature of the relation-
hips among the various participants involved in the chain, and on
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their implications for development. In practical terms, value chains
are descriptions of the transactions and processing of a product
until it reaches its end market, and will include various kinds of
processing, transportation and branding.
However, while this sounds like a neutral, technical process, a
key element of the value chain literature has been the recognition
that the various actors in the chain are likely to have greater or
lesser degrees of power, reﬂected in the kinds of incomes that each
earns but also in the characteristics of the ﬁnal product (Giuliani
et al., 2005; Kaplinsky, 2000). The impetus for value chain work
arose from the increasingly varied value chains that can be seen
for many products, both in terms of the addition of value (e.g.
from simple, undifferentiated agricultural commodities to highly-
processed, branded products) and the geographic distances that
they cover (e.g. from very localised markets to international ones).
Open access under CC BY-NC-ND license.A fundamental distinction in the value-chain literature is between
producer-driven chains and buyer-driven chains (Gerefﬁ, 1994).
This reﬂects the changing dynamics of the international trad-
ing system. For many commodities, changes in the regulation of
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nternational markets have increased competition among growers
nd traders, while, at the same time, it has become clear for cer-
ain value chains, ﬁnal markets have been dominated by certain
upermarkets or certain brands.
The focus of value chain research has been two-fold. One focus
as been to understand how different kinds of value chain confer
ompetitive advantage, by changing the way that a product is pro-
essed or sold (Recklies, 2001). Aside from this, value chain analysis
as been used as a tool for understanding socioeconomic beneﬁts,
isadvantages and risks for the various member of such a chain. This
econd approach has been used successfully, for example for under-
tanding the beneﬁts of gathering non-timber forest-products most
otably of plant and animal derived commodities with a high value
e.g. Wynberg et al., 2003), in the discussions about the beneﬁts
f Fairtrade products (e.g. Stiglitz and Myers, 2006), and generally
or assessing the relative beneﬁts of high value, medium volume
gro-forestry products like tea, coffee, and chocolate (e.g. Blowﬁeld,
004).
A key element of these debates has been an assessment of the
elative beneﬁts to the primary producers, as compared to mid-
lemen, wholesalers and retailers. Often it was found that farmers
r gatherers only obtained a minimal share in the beneﬁts of such
roducts (e.g. Litvinoff and Madeley, 2007).
Medicinal herbs, and the products derived from them, also seem
o have very varied value chains. However, despite the size of
rade in medicinal herbs and herbal products, surprisingly, very
ew studies have looked at the value chain. The WHO  has estimated
he demand for medicinal plants is approximately $14 billion per
nnum (2006) and the demand is growing at the rate of 15–25%
nnually. The WHO  estimates that by 2050 the trade will be up
o US$ 5 trillion. We  argue that the global value chain approach
s a valuable analytical tool in understanding the impact of these
hanging patterns of internal trade in medicinal herbs and herbal
roducts. This is despite the general criticisms that have been made
f the global value chain (GVC) approach (Bernstein and Campling,
006; Gilbert, 2008; Selwyn, 2007). Criticisms have focused on the
nability of a GVC analysis to explain consumption patterns and
or the inability to understand the general conditions of employ-
ent and production in poor countries. As such, a GVC approach
llows us only to look at a particular slice of economic production.
espite this, the value chain approach can help us understand the
inds of impacts associated with the production of medicinal herbal
roducts.
By understanding the external and internal linkages within
roduction, processing and trade networks, it is possible to under-
tand more clearly why the quality of herbal medicines may
ary in different markets. The concept of the value chain also
elps us understand the socio-economic impact of this grow-
ng international trade, by illuminating the very different returns
eceived by actors within different value chains. This commen-
ary sets out some basic research needs in this area and offers
 general model for assessing global value chains in herbal
edicine.
. Value chains of medicinal plants – evidence so far
While general reference to the topic of value chains is made
n some articles (e.g. Stewart, 2003; Winkler, 2008) and while
here is a relative abundance of reports on a range of food prod-
cts (incl., tea, coffee; e.g. Menon, 2008; Wynberg et al., 2003;
ryceson, 2008), only a limited number of studies on value chains
f herbal medicines exist. Two examples of research on regional
alue chains from South America with a strong ethnographical
ocus include Bussmann and Sharon (2009) and Revene et al. (2008).
lam and Belt (2009) looked at the ecological threats to resourcesmacology 140 (2012) 624– 633 625
with respect to medicinal plant species and their depletion at a
rapid pace due to over-collection from their natural habitats. The
collection and marketing of medicinal plants from the wild is an
important source of livelihood for many of the poor in developing
countries. For example in Nepal, more than three hundred thou-
sand households are engaged in the collection of medicinal plants.
A key outcome of their research has been the call for tightening
restrictions on collection practices and secondly through advocat-
ing cultivation on a large scale.
Alam and Belt (2009) work focused on a project in Uttarakhand,
northern India. It was  proposed that the cultivation of a medici-
nal plant, Kutki (Picrorhiza kurroa Royle ex Benth.), Plantaginaceae,
would beneﬁt the farmers ﬁnancially, provide social beneﬁts and
help preserve wild species. The European buyer would also bene-
ﬁt from having a secure supply of the plant from a fully traceable
source. Although the authors claim that this was  the ﬁrst initiative
of this kind between Indian farmers and a European company, there
have been similar partnerships established in the UK for some time
(Interview with Sebastian Pole, Pukka Herbs, 2011). The Uttarak-
hand project produced disappointing results and in their paper the
authors highlighted the reasons for this as being poor quality of
planting material, planting on small, poorly irrigated plots, and the
emergence of apples as a proﬁtable cash crop, resulting in farmers
switching from kutki to apples.
Alam and Belt (2009) conclude that the cultivation of medici-
nal plants is more difﬁcult than usually suggested in the scientiﬁc
literature and government promotional material and stress the
importance of agencies and NGOs taking these difﬁculties into
account and take steps to minimise these difﬁculties. The authors
further argue that, a thorough technical and economic feasibility
study of the value chain, long term involvement and an under-
standing of the prevalent farming systems are required to ensure
the success of the chain.
A more optimistic outlook with respect to the economic poten-
tial of medicinal plants in Bangladesh is provided by Shahidulla
and Haque (2010) who suggest that a vertical integration is needed
in order to beneﬁt producers and processors at the beginning of
the value chain. Their ﬁndings indicated that the primary and
wholesale secondary markets were dominated by middlemen and
their study challenged the view that medicinal plant cultivation
was  only appropriate for relatively well-off people with better
access to land, capital and information. The authors argue that
some of the mechanisms employed in developing and sustaining
institutional relationships may  also apply equally well to deﬁning
the medicinal plant value chain and list contracts, quasi-vertical
integration (especially close and long term relationship), tapered
vertical integration (when a company sources inputs externally
from independent suppliers as well as internally within the same
company), cost plus agreement (the contractor is paid a nego-
tiated amount regardless of incurred expenses), joint ventures
and strategic alliances as examples of these potential relation-
ships. Moreover, they argue that the beneﬁts of an integrated
value chain are numerous. It enables primary producers to become
active participants in the process, it removes market access barri-
ers, results in better commercialisation of products and is attractive
to companies as they can have greater control over quality and
supply.
Contrary to previous views of Alam and Belt (2009),  Shahidulla
and Haque (2010) found that the cultivation or production of
medicinal plants could play an important role in improving the
livelihoods of poor or extremely poor people owning meagre strips
of land. They argue that in order to sustain growth in medicinal
plant production, a fair distribution of the gross margin to the pri-
mary producers is necessary. In the value chain system examined,
it was found that downstream buyers, especially manufacturers
and consumers pay most of their money for middlemen’s value
626 A. Booker et al. / Journal of Ethnopharmacology 140 (2012) 624– 633
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dditive opportunistic pricing due to inherent weaknesses in the
hain. It is suggested that a vertically integrated chain, with only
roducers and processors as commercial actors and NGO’s as pro-
oters as shown in Fig. 1e and f (see the discussion below) could
reate an economically robust system which will beneﬁt the many
ather than the few.
One functional food or nutraceutical that seems to be working
ell for some groups of producers is green tea, a product mostly
onsumed as a health beverage, but which also has been associated
ith speciﬁc therapeutic beneﬁts. Presumably because of the high
emand for this relatively highly valued product and because of
ell established supply chains, many producers offer high-quality
reen tea products. It is widely reported that tea cultivation in the
ountries where it is prevalent has historically demonstrated a pos-
tive impact on the economy of the poorer rural areas (e.g. Ahmed
t al., 2010; Fairtrade, 2010; Overview, 2006; Carnegie Council for
thics in International Affairs, 2011). Tea cultivation often requires
ompanies to provide employment to large numbers of the least
rivileged segments of society, mostly in remote areas where there
s little other infrastructure. As a result, roads, electricity, water,
tc., become more widely available to the general populace in these
solated districts. In India for instance, the major tea plantation
ompanies provide affordable housing, medical care and education the herbal medicines and herbal medical products trade.
to their employees and their employees’ families. Wage agreements
are usually industry-wide and salaries are above the national aver-
age (Menon, 2008).
Green tea production is chieﬂy located in South–East Asia and
particularly in China, which is responsible for 75% of all green
tea produced (Overview, 2006). Although much of the Chinese
tea production is conducted on small farms rather than large tea
plantations, according to Liu (2010),  Unilever has invested tens
of millions of Yuan in establishing a research centre on tea and
traditional Chinese medicine in Anhui province. The plant has a
production capacity of more than US$ 15 million per annum.
Although this seems to be a win-win situation for rural work-
ers, as outlined below, there is a counter argument: the companies
are the major winners through their exploitation of the farmers
and their’ workers, who in turn have few alternatives other than
to subjugate themselves either to the multi-national or state run
companies (Morser, 2010) (see also below with respect to the Fair-
trade movement). They ﬁnd themselves increasingly dependent on
a wide range of exterior inputs ranging from seed to fertilisers to
pesticides (Vasquez, 2011). The relative bargaining power of pro-
ducers at the cultivation end of the value chain generally seems to
be relatively weak compared to the processors and retailers who
are able to exert control on both the price paid for the raw crops and
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he essential inputs needed to produce economically viable yields
Lines, 2006).
The future for the growth of green tea production is inextri-
ably linked to its health claims, but it is not only the health of
onsumers in Europe that are affected, but also the workers and
armers in the countries of origin. In Vietnam, tea producers often
eneﬁt from better living standards than producers of other crops
ith reports of incomes doubling through tea production (Agrifood,
004) However one key report suggests that the overuse of
esticides by producers leads to pesticide residue rates that far
xceed international limits exposing tea pickers to high levels of
oxins that are hazardous to health (SNV, 2010).
One initiative that seems to be having a beneﬁcial effect on both
he incomes of farmers and the quality of produce is the Fairtrade
cheme, which mostly covers agricultural food products. This has
een particularly noticeable in the tea and coffee markets and the
road based aim of the Fairtrade movement is to offer a better deal
or farmers by paying above the market rate for the commodity in
uestion and in return the farmers are expected to adhere to the
airtrade policies on production and follow quality-driven require-
ents in key areas, particularly in the cultivation and collection
tages. Although basically, this is to be welcomed the scheme is far
rom a panacea as it only represents a small section of the total
arket and may  be more suitable in some countries than others
Farnworth and Goodman, 2008).
Fairtrade schemes also tend to favour larger companies and,
espite of all attempts, have had little inﬂuence on the wages of
he poorest workers or farmers. In other words, Fairtrade seems to
avour the larger farms. One of the major reasons that the price of
ea can be kept so low is due to the domination of the tea sector by
 few companies and it is seen in the breakdown of who accrues
he largest share of the value chain that the highest earners are the
raders and retailers. According to the Fairtrade statistics (2010) in
he normal trade approximately 40% of the retail price of tea accrues
o the tea traders and manufacturers, and a further 40% goes to the
rocessors/blenders, packagers and retailers, based mainly in rich
ountries. In tea-producing countries, around 15% of the retail price
oes to the plantation and factory, and less than 1% to the auction
roker. The plantation worker is likely to earn 1% or less of the retail
alue. One central question is how can the green tea industry be
ustainably developed to optimise the health beneﬁts at both ends
f the supply chain? Workers and small farmers have historically
een weakened and marginalised and today hold a relatively minor
osition in the tea value chain. A downward pressure on the price
aid for tea to the farmers and subsequently on the daily wages of
he workers, causes poverty and distress among hundreds of thou-
ands of people whose living depends entirely on tea production.
t the same time traders and tea packers are continuing to realise
arge proﬁts (Oxfam, 2002). It is claimed that large companies have
 policy of deliberately reducing differences in quality among the
ifferent teas produced all over the world enabling teas to be pur-
hased at the lowest cost and maximising proﬁts from the blending,
ackaging and marketing stages which tend to be in the hands of
he large tea oligopolies (Oldenziel and Otten, 2006). There are cer-
ainly parallels to be drawn between tea and the medicinal plant
alue chain and the industry should be cautious of engendering
n industry that follows blindly in the footsteps of the tea trade.
chemes such as Fairtrade, although not perfect, have shown that
t is possible to develop a better working relationship with farm-
rs and that proﬁts can be distributed more fairly along the value
hain. This fairer trading approach can have beneﬁts to all actors
long the chain. The rewards for the farmers and producers at the
eginning of the chain are often the focus but there are also beneﬁts
or the retailers in terms of reaching a different target market and
ne that is often prepared to pay a premium price for more ethical
rading.macology 140 (2012) 624– 633 627
Based on our systematic review of the literature there seems to
be no systematic evaluation whether different value chains have an
impact on the quality and on the health beneﬁts of green tea prod-
ucts. Thus, overall and with the exception of a product like green
tea, there are very limited studies using the value chain concept
and it is mostly linked to research and policy implementation needs
in the context of sustainability and local livelihoods. The example
of green tea, on the other hand demonstrates the way in which a
value chain approach can illuminate a wider range of important
factors.
3. Value chains of medicinal plants – conceptual models
Since no systematic assessment of value chains of medicinal
plants exists, we  systematically compared various routes how
products reach a market (see Fig. 1). Based on the recent develop-
ments in the global markets of medicinal plants (Kala et al., 2006),
value chains that originate in some Asian countries and especially
in India and China are of particular interest.
In its most simple form, an ethnopharmacological value chain
may  simply link a healer with his or her patient (Fig. 1a). This
is, of course, what is found in many classical ethnopharmacolog-
ical studies which involve the investigation of local and traditional
knowledge. In essence the healer is the prescriber and supplier
of a plant to be used as a medicine (or he advises the patient
on what to collect and use). If such a medicine is supplied it
may be grown or collected by the healer and – especially in
certain systems – the herbal material may  be subject to often com-
plex processing. Generally a healer has detailed knowledge about
these plants and will be able to identify it properly as well as
ascertaining that it is of a culturally acceptable composition and
quality.
Very often such healers are now relying on some sort of small
scale local trade to secure the material they are prescribing or pro-
cessing (Fig. 1b). Clearly this has an impact on the quality of a
product, how this quality is monitored, and how value is generated
from it. It also may  have important implications on the sustain-
ability of use and impact on a species’ availability as a commodity.
Obviously, this also impacts on the value of the product and the
economic beneﬁts made from it or its cost to the patient, respec-
tively.
These two  differ from all other examples in Fig. 1, by in essence
relying exclusively on small local networks and on one to one relation-
ships between the partners. As shown in Fig. 1c and d, more complex
value chains generally involve middlemen who are likely to pro-
cure material from a wider range of primary producers (farmers
or gatherers). In this case the middlemen in essence serve as a
bridge between the primary producer and the retailer or end user.
Of course, there may  well be various levels of middlemen, which
build up a supply chain for a speciﬁc product or more commonly
a range of products. Such middlemen often also serve as money
lenders or as suppliers of industrial goods which are sold in the local
communities. The key difference between the two ﬁgures (Fig. 1c
and d) is that one is essentially a national chain, while the other
one integrates the consumers into the international or global mar-
kets structures. It also highlights that, if this is the case, there will
be a national and an international supply chain. As before the dif-
ferences between these two  groups may  often be blurred, and are
likely to change over time. This value chain has a certain similar-
ity to the ones for high value, medium volume products like tea or
coffee.The ﬁnal two possibilities highlight and increased industriali-
sation of the process. In one case (Fig. 1e) several companies are
involved throughout the supply chain (tapered vertical integra-
tion). Alternatively, it may  be that the whole process is largely in
628 A. Booker et al. / Journal of Ethnopharmacology 140 (2012) 624– 633
Table 1
Probability that the retailer or practitioner at the end of the value chain has control over the given inputs in the various parts of the value chains as outlined in Fig. 1. This
control  includes the products value, but as importantly its quality (and thus safety). With an increasing reliance on more and more complex value chains there will have to
be  new measures that need to be implemented in order to ascertain such a control.
A B C D E F
Local control of quality parameters ∗∗∗∗∗ ∗∗∗ ∗∗ ∗ ∗ ∗
GACP (Good agricultural and collection practice) n.a. n.a. ∗∗ ∗∗∗ ∗∗∗∗ ∗∗∗∗
Traceability ∗∗∗∗ ∗∗ ∗ ∗∗∗ ∗∗∗∗ ∗∗∗∗∗
Pesticide usage ∗∗∗∗ ∗∗ ∗∗ ∗∗∗ ∗∗∗ ∗∗∗∗
Storage conditions ∗∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗∗
Distribution ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗∗∗
GMP  (Good Manufacturing practice) n.a. ∗ ∗ ∗∗∗ ∗∗∗ ∗∗∗∗
Process control ∗∗∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗∗ ∗∗∗∗
Analytical testing n.a. ∗ ∗ ∗∗ ∗∗∗∗ ∗∗∗∗∗
Documentation ∗∗ ∗∗ ∗∗ ∗∗∗ ∗∗∗ ∗∗∗∗∗
Pharmacovigilance n.a. n.a ∗ ∗ ∗∗ ∗∗
n.a.; Not applicable.
* Very unlikely.
** Unlikely.
*** Probable.
****
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he hands of or controlled by one company, normally one well-
laced at the end of the supply chain (Fig. 1f) (e.g. a pharmaceutical
roducer or a large retailer).
This simpliﬁed model suggests that individual producers who
row and use their own medicinal plants have a reasonable amount
f control over quality inputs within the chain, this control is lost
s more middlemen and steps are introduced and then recovered
ith some additional inputs as a vertically integrated chain is estab-
ished.
Contrary to the examples of value chains in other sectors dis-
ussed above, value chains in the ﬁeld of herbal medicines vary
remendously in their structure. Rather than a simple contrast of
eing a producer-driven or buyer-driven chain, there are likely to
e a range of different relationships. This has implications on all
evels, including the social and economic conditions, the welfare of
hose involved in production and processing, as well as trade ﬂows
etween individuals, companies and nations, all aspects of quality
ssurance and in a very broad sense on the governance in the area
f herbal medical products (see Table 1). This table highlights the
evel of control a user at the end of the value chain (e.g. a healer, a
edical doctor or other practitioners or a retailer) has on param-
ters that impact on the quality and consequently, the safety of a
roduct which goes through the value chains presented in Fig. 1a–f.
hile these are in essence theoretical postulations, they are based
n the data retrieved in our search and on information received
rom stakeholders in the sector. The assessment in Table 1 should
herefore serve as a starting point for systematic research into this.
ood agricultural and collection practice (WHO, 2003), for exam-
le, is relevant for complex supply chains, and often is particularly
ell developed in industrial value chains like the ones shown in
ig. 1e and f. Clearly this also strongly impacts on cultural and eco-
ogical conditions for those who are the primary producers of these
aterials.
The EU’s Traditional Herbal Medical Product Directive, for exam-
le, is, among other assumptions, based on the implicit recognition
hat the market for herbal medical products has been changing
nd has become reliant on much more complex and interrelated
alue chains. This concept of value chains and how they change in
esponse to market forces can be demonstrated very well in looking
t the recent developments in key producer and consumer coun-
ries of herbal medicines – India and China (e.g. Kala et al., 2006;
lam and Belt, 2009; Shahidulla and Haque, 2010; Ravishankar and
hukla, 2007; Vaidya and Devasagayam, 2007; Giuliani et al., 2005;
aplinsky, 2000).4. Examples of medicinal plant production in India and
China
In India herbal medicines are produced by several thousand,
mostly quite small companies, including numerous neighbourhood
pharmacies that compound ingredients to make their own reme-
dies (similar to our model 1c). Kala et al. (2006) assert that of
the 17,000 higher plants to be found in India, 7500 are known for
medicinal uses, with Ayurvedic medicine claiming to use 2000 of
these, most of which are collected from the wild. More than 60
species are in great demand and the so-called tribal belt of India
is abundant in these plants and these minorities (ethnic groups)
mainly depend on this trade for their lively hoods. More complex
value chains (like our models (E and F) are likely to be mostly of
relevance for these sixty species. Adulteration and contamination
is commonplace and so the supply of good quality raw materials is
limited. This limitation on good quality raw materials has stunted
the industry’s growth in previous years.
More and more species are being gradually added to the materia
medica and the standards for purity and identiﬁcation do not always
keep pace with this expansion process. It is estimated that the total
value of products from the entire herbal production in India is in
the order of US$ 1 billion. The industry has been dominated by
less than a dozen major companies for decades, joined recently
by a few others that have followed their lead. Ayurvedic medicine
production in India is dominated by three companies that produce
about 85% of the Indian domestic market: Dabur, Baidyanath, and
Zandu. The products of these companies are included within the
broad category of “fast moving consumer goods” (FMCG) which
mainly involves foods, beverages, toiletries, cigarettes, etc. Most
of the larger herbal medicine suppliers provide materials other
than herbal medicines, particularly in the areas of foods and toi-
letries (Dharmananda, 2003). According to Polshettiwar (2006) in
India, there are about another 20 well-recognized manufactures
of herbal drugs and 140 medium or small-scale manufactures. In
addition, thousands of vaidyas (traditional healers) have their own
miniature manufacturing facilities. About 1200 licensed small man-
ufactures in India are on record. India contributes less than 1% to
the global herbal market; however, it is fast emerging as a key sup-
plier of medicinal plants across the globe. The Indian Traditional
Herbal Medicines Act, 2006 regulates the sale of the traditional
herbal medicines which are marketed without any licence and con-
trol on the basis of being from ancient texts. According to the act
every retailer or seller of traditional herbal medicines needs to have
opharmacology 140 (2012) 624– 633 629
a
a
A
a
f
o
A
i
(
s
I
m
o
S
d
T
f
2
t
o
i
v
p
d
&
i
d
r
w
q
d
e
t
a
t
p
e
p
e
t
l
t
p
e
w
I
g
t
n
e
(
n
p
t
P
d
p
c
p
(A. Booker et al. / Journal of Ethn
 licence to sell traditional herbal medicines from the competent
uthority (Mukherjee et al., 2007). A national organisation ‘The
yurvedic Drugs Manufacturers Association’ is reportedly taking
 pro-active role to improve quality and research but is in need of
unding if it is to make any signiﬁcant contribution.
However, while Ayurveda has traditionally been the province
f home remedies (or short value chains), producers of such
yurvedic and other herbal medical products are going increas-
ngly ‘high-tech’ (Seale, 2011) and aim for wider commercialisation
e.g. Mukherjee et al., 2009). Also there is now a strong empha-
is on expanding these markets. Exports of herbal products from
ndia increased to from US$ 69 million in 2005–06 to US$ 128
illion in 2009–10, recording a compounded annual growth rate
f 16.8% (Scindia, 2010). USA, Pakistan, Germany, Japan, the UK,
pain, China, France, Vietnam, Mexico, were the top ten export
estinations for India’s herbal exports over the last three years.
he United Kingdom remained the ﬁfth largest overseas market
or Indian herbal products with exports worth US$ 3.7 million in
007–08, and US$ 5 million in 2008–09. The UK had a 2.5% share in
he country’s total herbal exports in 2009–10 (Scindia, 2010).
Taking these data together, it is apparent that India is fast devel-
ping a complex and mutually dependent national and export
ndustry. Originating from many small and practitioner controlled
alue chains, the market is now dominated by some key industrial
layers.
The Department of Ayurveda, Yoga & Naturopathy, Unani, Sid-
ha and Homoeopathy (AYUSH) within the Ministry of Health
 Family Welfare is focussing on its regulation and on the
mprovement of standards in the areas of quality control and stan-
ardisation of drugs, improving the availability of raw materials,
esearch and development, education/training of professionals and
ider outreach about these traditional medical systems.
Pharmacopoeia Committees have been established to develop
uality standards for the main groups of therapeutically relevant
rugs of Ayurveda, Unani, Siddha and Homoeopathy (Mukherjee
t al., 2007).
The Indian Government also established an independent body –
he “National Medicinal Plants Board” under the Ministry of Health
nd Family Welfare. It is responsible for co-ordinating all mat-
ers relating to the development of medicinal plants, including
olicies and strategies for conservation, proper harvesting, cost-
ffective cultivation and marketing of raw materials in order to
rotect, sustain and develop this sector. Uniquely, the Indian gov-
rnment has established programmes for the documentation of
raditional Indian knowledge, which is already available in pub-
ic domain. The political goal is to safeguard the sovereignty of this
raditional knowledge and to protect them from being misused in
atenting on non-patentable inventions. The Traditional Knowl-
dge Digital Library (TKDL) is an original proprietary database,
hich is fully protected under national and international laws of
ntellectual Property Rights and is maintained and developed by the
overnment. TKDL also allows automatic conversion of informa-
ion from Sanskrit into various languages. The information includes
ames of plants, Ayurvedic description of diseases under their mod-
rn names and therapeutic formulations (Mukherjee et al., 2007)
Fig. 2).
China has a longer history of cultivating and marketing medici-
al plants compared with India. There are hundreds of companies
roducing traditional Chinese medicines, many of which export
heir products internationally. On the one hand, according to
atwardhan (2005) India should take the lead from China in
eveloping a more quality driven ethos towards medicinal plant
roduction. However, China has overcome its own difﬁculties by
ontinuously and vigorously modernising its traditional medicines
rofession with government sponsored Good Agricultural Policies
GAP’s) and Good Manufacturing Practices (GMP’s).Fig. 2. Location of main medicinal plant manufacturers in India ().
The government has introduced a policy where all manufactur-
ers of TCM products must comply with standards set down by the
State Food and Drugs Administration (SFDA) in order to gain GMP
certiﬁcation. Only around 1500 companies have achieved this stan-
dard. Chinese attitudes to medicinal herb production are changing
rapidly. There is some evidence to indicate that Chinese farmers
and pickers are beginning to move away from the traditional route
of selling their herbs at the local or provincial herb markets and are
beginning to form alliances with local pharmaceutical companies
or with regional sourcing companies in order to gain access to the
more lucrative export market. Thus the value chains are changing
(cf. Fig. 1). For the farmer the beneﬁt to this approach is that the
buyer can give targets for the farmer to aim for and agree a price
at the time that will not be affected by many of the market shocks
that impact the market traders. With the assistance of academic
institutions and NGO’s, local companies are able to provide advice
and support to farmers on growing techniques including the cor-
rect use of fertilisers and pesticides. By paying an agreed price for
an assured quantity of herbs the buyer can expect to have some
input and control over the quality of the herb material; the sourc-
ing company can ask for crops to be collected at certain times of the
year and that they be collected, dried and stored in accordance with
the buyer’s speciﬁcation. This seems to be a logical and pragmatic
approach to satisfying both the demands of international trade and
the need to assure consistent and stable price structures. However,
one has to argue whether the regulatory processes are in fact keep-
ing pace with these changing supply and value chains. Clearly, this
approach is a long way from replacing traditional market systems
as it is the very nature of an unstable and ﬂuctuating market that
continues to attract and sustain interest in the medicinal plant trade
at the market level for many traders who use medicinal plants as a
commodity resource.
Both nations have been impacted by the European Union’s
Traditional Herbal Medicines Directive, 2006 which regulates the
sale of traditional herbal medicines which are marketed without
any licence and control on the basis of being from ancient texts.
According to the act every retailer or seller of traditional herbal
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aig. 3. The herbal practitioner value chain of crude botanical materials begins with
oves  along the chain, value is added in terms of costs and proﬁts to the producer
ased  on values for 20 randomly selected commonly used East Asian herbs with a
April  2011), a UK TCM supplier and UK practitioner clinics (November 2011)).
edicines needs to have a licence to sell traditional herbal
edicines from the Authority. Every manufacturer of traditional
erbal medicine needs to work under the principles of GMP, hav-
ng to list the ingredients of each medicine on the packaging
f the medicine along with the exact quantity. Side effects and
arnings of contraindications need to be stated on the package,
dding complexity to the value chain.erb grower in Asia and ﬁnishes with the consumer in Europe. As the herb material
t is the consumer who  will eventually pay for these costs and value added. (Prices
market price equivalent of £ 0.5–7.0. Survey locations – Bozhou TCM market PRC
Pharmaco-economic studies on TIM and TCM are rare but can
help in understanding cost-effectiveness and cost beneﬁt of tradi-
tional medicine. Patwardhan (2005) argue that in all such attempts,
Chinese medicine can help India at various levels, including
policies, quality standards, integration practices, research models
and integration into the health system. There is no doubt that China
has a lot of experience in this arena but it may  also be productive
A. Booker et al. / Journal of Ethnopharmacology 140 (2012) 624– 633 631
Fig. 4. The value chain for OTC turmeric products found in UK retail outlets.
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Table 2
Values of medicinal plants at different stages of supply.
Pinyin drug name Scientiﬁc name Market price in
China (£/kg)
UK supplier price
(£/kg)
Bai Zi Ren Platycladus orientalis (L.) Franco (Cupressaceae) 6.80 24.60
Bai  Shao Yao Paeonia lactiﬂora Pall. (Paeoniaceae) 2.00 15.00
Bai  Zhu Atractylodes macrocephala Koidz. (Asteraceae) 4.30 21.80
Bai  Xian Pi Dictamnus dasycarpus Turcz. (Rutaceae) 3.40 19.80
Bai  He Lilium lancifolium Thunb. (Liliaceae) 4.00 30.00
Ban  Lan Gen Isatis tinctoria L. (Brassicaceae) 1.20 7.80
Bo  He Mentha haplocalyx Briq. (Lamiaceae) 1.50 5.80
Cang  Zhu Atractylodes lancea (Thunb) DC. (Asteraceae) 3.10 15.40
Chai  Hu Bupleurum scorzonerifolium Willd. or Bupleurum chinense DC. (Apiaceae) 5.50 31.40
Che  Qian Zi Plantago asiatica L. (Plantaginaceae) 2.00 9.80
Chen  Pi Citrus reticulata Blanco (Rutaceae) 0.50 5.00
Chi  Shao Yao Paeonia lactiﬂora Pall. (Paeoniaceae) 2.60 18.00
Ci  Wu Jia Eleutherococcus senticosus (Rupr. & Maxim.) Maxim [syn.: Acanthopanax senticosus Harms.) (Araliaceae)] 0.60 5.00
Da  Huang Rheum palmatum L. or Rheum tanguticum Maxim. ex Balf. and Rheum ofﬁcinale Baill. (Polygonaceae) 0.50 11.00
Dan  Shen Salvia miltiorrhiza Bge. (Lamiaceae) 1.20 10.00
Dang  Shen Codonopsis pilosula (Franch.) Nannf. (Campanulaceae) 4.60 50.00
Dang  Gui Angelica sinensis (Oliv.) Diels. (Apiaceae) 2.50 23.00
Du  Huo Angelica pubescens Maxim.f. biserrata Shan ex Yuan (Apiaceae) 0.80 32.00
Du  Zhong Eucommia ulmoides Oliv. (Eucommiaceae) 1.60 11.00
Mu  Dan Pi Paeonia suffruticosa Andr. (Paeoniaceae) 2.00 19.00
Mean  2.54 18.3
SD  1.78 11.4
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 Price per kilo of crude powdered turmeric.
xchange rate £1 = 10 RMB, December 2011.
or India to make collaborations with the countries in which their
roducts are destined in order that they can fully comply with
nternational standards and regulations. Clearly such pharmaco-
conomic approaches are another outcome of an understanding of
he value chains of Indian and Chinese products entering national
nd international trade.
. Examples of current international medicinal plant value
hains
Two examples of medicinal plant value chains are described
ere, one for the practitioner route using values for twenty com-
only prescribed herbs used in TCM (Fig. 3, and Table 2) and the
ther for an over the counter route using a single herbal ingredi-
nt, Curcuma longa (Turmeric), found chieﬂy in Traditional Indian
edicine, as a case study (Fig. 4). In the ﬁrst example, the value of
he herbs increases dramatically as the product moves away from
he farmer and towards the consumer (Fig. 3). The farmers are often
he same individuals who sell the botanical drugs in the market.
n this example there is no ‘value addition’ due to processing, as
he ﬁnal product is in the same product – a crude dried herb –
s when it started. Therefore, the price increments are due to costs
ncurred through externalities, price increases through middlemen
nd value added in terms of professional knowledge.
This is in contrast to the process outlined in Fig. 4 where the over
he counter (OTC) products have value added chieﬂy through differ-
nt cultivation and processing methods. All of the ﬁnished products
ere purchased from UK retail outlets. Notably there is a ten-
old increase for simply encapsulating the powder for convenience
nd to give the appearance of a medicinal product rather than a
ood ingredient. Prices continue to increase as more specialised
ultivation and extraction methods are used. Further studies are
lanned to understand whether there are any differences in chem-
stry between products.
. ConclusionOur central aim in this commentary is to draw attention to
ome key issues in medicinal plant research/ethnopharmacology,
hich has largely been overlooked in the scientiﬁc debate: the0101220.
role of value chains. The literature in this area is often pub-
lished in NGO and other reports and, therefore, this review cannot
be comprehensive. However, it is obvious that in the area of
medicinal plant research there is a gap in terms of analysing the
value chains which exist for herbal medical products very often
harvested from the wild or produced in small scale agricultural
practices.
From a pharmacognostic perspective this has crucial impli-
cations for the way  regulations of such products ought to be
developed and on the strategies for quality assurance (esp. as it
relates to controlling the overall supply chain). There also is a gap
in our understanding on the impact that the gathering or grow-
ing of such products has for local household economies and how
the beneﬁts are shared (or not shared) throughout the value chain.
The conceptual framework we propose in Fig. 1 also helps in under-
standing the change when local medicinal (and food) plants become
global commodities (Heinrich et al., 2011; Obolskiy et al., 2009;
Gomez-Castellanosa et al., 2009). The value chains for herbal med-
ical products have some unique characteristics, which seem to have
had little impact on the discussion about value chains in the socioe-
conomic and developmental politics literature. This is a market
often dominated by small and medium sized enterprises, and one
which is governed by diverse regulations relating to the products
quality and health claims, which vary widely throughout the world
(Heinrich et al., 2004). Very often these regulations are relatively
stringent (as in the case of the EU’s THMPD) but in other cases
there is a very limited control over the ﬁnal products brought to
the consumers.
The analytical framework we propose allows an understand-
ing of how the changing pattern of commercialisation changes the
value chain, and what impact this has on the various elements of
the chain from local producing householders to end user. At the
same time, the approach helps us understand the way that changes
to value chains may  fundamentally change the product and its
quality. Conversely product requirements and quality standards as
well as other regulatory requirements have an important impact
on the value chain. Indeed, the impact of this complex regulatory
framework differentiates the value chains of these agricultural and
wild-crafted products from other forms of production and distri-
bution.
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